Ipsen 5i is a Novel Potent Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants.
about
How genetic errors in GPCRs affect their function: Possible therapeutic strategiesDefect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene.Latest approaches for the treatment of obesity.Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo.Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.
P2860
Ipsen 5i is a Novel Potent Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@ast
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@en
type
label
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@ast
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@en
prefLabel
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@ast
Ipsen 5i is a Novel Potent Pha ...... lanocortin-4 Receptor Mutants.
@en
P2860
P356
P1476
Ipsen 5i is a Novel Potent Pha ...... elanocortin-4 Receptor Mutants
@en
P2093
P2860
P356
10.3389/FENDO.2014.00131
P50
P577
2014-08-04T00:00:00Z